Strategic clinical utility Position PROphet NSCLC as a decision-support tool that directly influences first-line immunotherapy choices, highlighting potential to expand adoption across oncology centers seeking evidence-based, individualized treatment plans.

Clinical trial traction Leverage the large-scale prospective trial footprint (40+ sites, 1,700 patients) to validate and market real-world outcomes, offering hospitals and networks robust data to support payer negotiations and adoption.

Awards credibility Highlight recent AI and innovation awards (Artificial Intelligence Excellence Awards, BIG Innovation Award, Top 10 Innovator) to build trust with buyers, payers, and academic partners seeking proven, externally recognized technology.

Funding and growth signals With revenue in the lower mid-range and modest external funding, target growth-stage health systems and regional networks looking for cost-effective precision diagnostics to differentiate offerings and drive clinical outcomes.

Tech-enabled partnerships Emphasize cloud-based, proteomics-driven platform capabilities and existing tech stack (AWS, MySQL, PHP) to position for integrations with hospital EHRs, LIS, and biobank collaborators, enabling streamlined implementation and data interoperability.